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Background: Claudin(CLDN)18.2 is a stomach specific tight junction protein. The chimeric monoclonal 
anti-CLDN18.2 antibody IMAB362 potently activates complement and antibody dependent cellular 
cytotoxicity. FAST investigated CLDN18.2 tumor expression and therapy with IMAB362 in combination 
with first line chemotherapy in pts with advanced gastric and GEJ cancer. 
Methods: Pts with advanced gastric and GEJ cancer were centrally evaluated for CLDN18.2 by 
immunohistochemistry (CLAUDETECT18.2® Kit). CLDN18.2 expression of ≥ 2+ in ≥ 40% tumor cells was 
defined positive. Eligible pts required CLDN18.2+ tumors, an ECOG PS of 0–1, and no medical need for 
trastuzumab treatment. Pts were randomized 1:1 to first line EOX (epirubicin 50 mg/m2, oxaliplatin 
130 mg/m2 d1, and capecitabine 625 mg/m2 bid, d1–21; qd22) with... 
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